Quick Ratio: Aeterna Zentaris Inc (AEZS)

A stable roster of patent experts, combined with sustainable manufacturing and strict bioethical oversight, forms the foundation of Aeterna Zentaris (AEZS). This price chart illustrating value trends demonstrates the asset's dynamics, where the liquidity ratio is 0.00. The business relies on the implementation of the non-invasive Macrilen test, which has become a benchmark tool for endocrinologists in detecting growth hormone deficiency.

For Aeterna Zentaris (AEZS), which is transforming its portfolio toward rare orphan therapies, the quick ratio on GURU.Markets serves as an indicator of financial autonomy. This metric assesses the company's ability to settle short-term obligations using only its most liquid assets. The calculation excludes inventories, focusing instead on the ratio of cash and accounts receivable to current liabilities. This allows for a determination of real capital stability as the company exits low-margin pharmaceutical niches.